Biofil Chemicals and Pharmaceuticals Limited (BOM:524396)
India · Delayed Price · Currency is INR 31.70
0.00 (0.00%)
At close: Sep 4, 2026
BOM:524396 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 343.13 | 283.95 | 334.02 | 400.35 | 300.35 | 223.82 |
Other Revenue | 3.13 | -0 | 1.8 | 3.73 | - | - |
| 346.26 | 283.95 | 335.82 | 404.09 | 300.35 | 223.82 | |
Revenue Growth | 1.26% | -15.45% | -16.89% | 34.54% | 34.19% | -37.50% |
Cost of Revenue | 321.42 | 261.14 | 310.16 | 376.61 | 274.72 | 195.16 |
Gross Profit | 24.83 | 22.81 | 25.67 | 27.48 | 25.63 | 28.66 |
Selling, General & Admin | 13.86 | 8.11 | 7.97 | 6.82 | 6.34 | 7.94 |
Other Operating Expenses | - | 7.04 | 6.62 | 7.66 | 6.66 | 6.1 |
Operating Expenses | 16.61 | 17.86 | 18.38 | 18.47 | 17.29 | 18.32 |
Operating Income | 8.23 | 4.95 | 7.29 | 9 | 8.34 | 10.34 |
Interest Expense | -0.02 | -0.09 | -0.36 | -0.4 | -0.42 | -0.39 |
Interest & Investment Income | - | 1.53 | 0.44 | 0.07 | 0.02 | 0.21 |
Other Non Operating Income (Expenses) | - | -0.01 | -0.01 | -0.02 | -0.01 | -0.02 |
EBT Excluding Unusual Items | 8.21 | 6.38 | 7.36 | 8.65 | 7.93 | 10.15 |
Gain (Loss) on Sale of Assets | - | 28.12 | - | - | - | - |
Pretax Income | 8.21 | 34.5 | 7.36 | 8.65 | 7.93 | 10.15 |
Income Tax Expense | 3.37 | 6.64 | 1.78 | 1.56 | 2.33 | 3.17 |
Net Income | 4.84 | 27.86 | 5.58 | 7.09 | 5.6 | 6.98 |
Net Income to Common | 4.84 | 27.86 | 5.58 | 7.09 | 5.6 | 6.98 |
Net Income Growth | -82.71% | 399.55% | -21.36% | 26.55% | -19.76% | -43.74% |
Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 | 16 |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 | 16 |
Shares Change | -0.80% | - | - | - | - | - |
EPS (Basic) | 0.30 | 1.71 | 0.34 | 0.44 | 0.34 | 0.43 |
EPS (Diluted) | 0.30 | 1.71 | 0.34 | 0.44 | 0.34 | 0.43 |
EPS Growth | -82.57% | 402.94% | -21.98% | 28.17% | -20.77% | -43.74% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -8.05 | -20.24 | 23.71 | -1.22 | -2.9 |
Free Cash Flow Per Share | - | -0.49 | -1.24 | 1.46 | -0.07 | -0.18 |
Gross Margin | 7.17% | 8.03% | 7.64% | 6.80% | 8.53% | 12.80% |
Operating Margin | 2.38% | 1.74% | 2.17% | 2.23% | 2.78% | 4.62% |
Profit Margin | 1.40% | 9.81% | 1.66% | 1.75% | 1.87% | 3.12% |
Free Cash Flow Margin | - | -2.84% | -6.03% | 5.87% | -0.41% | -1.29% |
EBITDA | 10.68 | 7.67 | 11.08 | 13 | 12.63 | 14.62 |
EBITDA Margin | 3.08% | 2.70% | 3.30% | 3.22% | 4.21% | 6.53% |
D&A For EBITDA | 2.45 | 2.72 | 3.8 | 3.99 | 4.29 | 4.28 |
EBIT | 8.23 | 4.95 | 7.29 | 9 | 8.34 | 10.34 |
EBIT Margin | 2.38% | 1.74% | 2.17% | 2.23% | 2.78% | 4.62% |
Effective Tax Rate | 41.05% | 19.24% | 24.23% | 18.04% | 29.33% | 31.19% |
Revenue as Reported | 346.26 | 314.78 | 337.07 | 405.25 | 301.32 | 225.33 |
Advertising Expenses | - | 0.11 | 0.12 | 0.12 | 0.1 | 0.07 |